Nuwellis Q2 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $1.7 million, a 21% decline year-over-year from $2.2 million in Q2 2024.

Pediatric Revenue: Increased by 23% compared to Q2 2024.

Heart Failure Revenue: Declined by 53%.

Critical Care Revenue: Declined by 35%.

Gross Margin: 55.5%, down from 67.2% in Q2 2024, primarily due to lower production volumes.

Operating Loss: $2.9 million, compared to $2.3 million in Q2 2024.

Net Loss: $12.6 million, or a loss of $60.99 per share, compared to a net loss of $7.7 million or $791.82 per share in the same period last year.

Cash Position: Ended the quarter with $4.5 million in cash and cash equivalents, remaining debt-free.

2Strategic Updates and Business Highlights

The company focused on operational discipline and strategic investments to enhance growth potential.

Addressed a temporary back order of $400,000 due to sterilization vendor issues, which has since been resolved.

Pediatric business remains strong, with ongoing interest from new hospital centers.

Transitioning manufacturing to KDI Precision Manufacturing, expected to yield operational efficiencies and cost savings.

Terminated the REVERSE-HF clinical trial to reallocate $4 million toward higher impact growth areas, not due to device performance or safety concerns.

3Forward Guidance and Outlook

The company aims to progress towards cash flow positivity and meet commercial targets in pediatrics and cardiac surgery.

Plans to deepen outpatient engagement in heart failure programs, leveraging increased reimbursement rates for outpatient treatments.

Confidence in the growth potential across all three segments: pediatrics, critical care, and heart failure.

4Bad News, Challenges, or Points of Concern

The overall revenue decline reflects significant headwinds, particularly in heart failure and critical care segments.

Gross margin contraction due to under-absorption of fixed overhead linked to lower production volumes.

The company faces challenges in scaling operations, particularly in outpatient heart failure due to staffing and space constraints.

5Notable Q&A Insights

The back order issue was resolved in the first week of July, and inventory is being built up in preparation for the transition to KDI Manufacturing.

CEO John Erb highlighted that while all three business segments present opportunities, the fastest growth is anticipated in outpatient heart failure due to improved reimbursement rates and hospital interest in setting up outpatient clinics. Overall, while Nuwellis is navigating some challenges, particularly in revenue and margins, it is positioning itself for future growth through strategic initiatives and a focus on key market segments.